Live Breaking News & Updates on International Coordinating Investigator Prof

Stay updated with breaking news from International coordinating investigator prof. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

CatalYm Presents Positive Phase 2a Outcome for Visugromab in Advanced NSCLC and Urothelial Cancer at the ESMO Immuno-Oncology Congress 2023

CatalYm Presents Positive Phase 2a Outcome for Visugromab in Advanced NSCLC and Urothelial Cancer at the ESMO Immuno-Oncology Congress 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Ignacio Melero , Phil Lhuillier , Catalym Gmb , Oncology Congress , Department Of Immunology , International Coordinating Investigator Prof , European Society For Medical Oncology , Trophic Communications , Objective Response Rates , Ted Human Effector Cell Relocation Phase , European Society , Medical Oncology , Immuno Oncology Congress , Growth Differentiation , International Coordinating Investigator , Universidad De Navarra , Professor Eugen Leo , Chief Medical Officer , Objective Response Rate , Tumor Proportion Score , Treatment Emergent Adverse Events , Serious Adverse Reaction , Treatment Related Adverse Event , Phill Huillier , Managing Director , Chief Executing Officer ,

CatalYm Announces Initial Data from Ongoing Phase 2a Trial Evaluating GDF-15-targeting Antibody Visugromab in Combination with Nivolumab at ASCO 2023

Oral presentation highlights first data from the GDFATHER-2a trial demonstrating lasting and confirmed responses (as per RECIST criteria) following treatment with visugromab and the anti-PD-1 inhibitor ....

Mecklenburg Vorpommern , United States , Phil Lhuilier , Ignacio Melero Bermejo , Phil Lhuillier , Stefan Klotter , Catalym Gmb , International Coordinating Investigator Prof , American Society Of Clinical Oncology , Trophic Communications , Ted Human Effector Cell Relocation Phase , American Society , Clinical Oncology , Annual Meeting , Growth Differentiation , Eugen Leo , Chief Medical Officer , International Coordinating Investigator , Universidad De Navarra , Phill Huillier , Chief Executive Officer , Phill Huilier , Stephanie May , Stabile Ertr , Chart Profi Stefan Klotter , Blue Chips ,

CatalYm GmbH: CatalYm Demonstrates Clinical Efficacy and Tolerability in First-in-Human Phase 1 Trial for Visugromab and Nivolumab Combination

In an oral presentation at ESMO 2022, data from the GDFATHER-1 trial showed that treatment with visugromab and the anti-PD-1 inhibitor nivolumab resulted in excellent tolerability and significant anti-tumor ....

France General , Kostenloser Wertpapierhandel , Catalym Gmb , Ignacio Melero Bermejo , Phil Lhuillier , Phil Lhuilier , International Coordinating Investigator Prof , Trophic Communications , European Society For Medical Oncology , European Society , Medical Oncology , International Coordinating Investigator , Universidad De Navarra , Eugen Leo , Chief Medical Officer , Phill Huillier , Chief Executive Officer , Clinical Benefit Rate , Ted Human Effector , Growth Differentiation , Phill Huilier , Stephanie May ,